Overview

Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC

Status:
Terminated
Trial end date:
2021-04-15
Target enrollment:
Participant gender:
Summary
The aim of this trial is to assess if patients treated with the combination of ribociclib and endocrine therapy respond to treatment as fast as patients treated with chemotherapy only, without decreasing their quality of life (QoL).
Phase:
Phase 3
Details
Lead Sponsor:
Swiss Group for Clinical Cancer Research
Collaborator:
The Belgian Society of Medical Oncology